QLT Inc. is a Canada-based biotechnology Company. The Company is engaged in the development and commercialization of ocular products. The Company is focused on developing its synthetic retinoid program for the treatment of certain inherited retinal diseases. The Company is engaged in providing transition services to Valeant concerning most of the aspects of the Visudyne and Qcellus laser business. The Company is conducting Phase Ib clinical proof-of-concept studies of QLT091001, a synthetic retinoid replacement therapy for 11-cis-retinal, a key biochemical component of the visual retinoid cycle, in patients with Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). The Company’s product Visudyne and Eligard are sold to Valeant Pharmaceuticals International, Inc and QLT USA, Inc. respectively.